IL-1RN-2018多态性及IL-1Ra/IL-1β比值与非小细胞肺癌的关系

Association between IL-1RN-2018 gene polymorphism and IL-1Ra/IL-1β with non-small cell lung cancer

目的探讨白细胞介素受体拮抗剂(IL-1Ra)编码基因2018(IL-1RN-2018)多态性及血清IL-1Ra/IL-1β比值与非小细胞肺癌(NSCLC)的相关性。方法 2012年1月至2014年1月选取85例NSCLC患者作为NSCLC组,80例健康体检者作为对照组,采用荧光定量PCR为基础的高分辨率熔解曲线(HRM)技术检测IL-1RN-2018T/C基因SNP,随机选取10%进行基因测序验证,应用ELISA法测定两组血清中IL-1Ra及IL-1β水平。结果 (1)NSCLC组患者IL-1RN-2018基因的TC型、TC+CC型的NSCLC发病风险分别为TT型的2.646倍和2.315倍,差异有统计学意义(P<0.05)。(2)鳞癌患者与腺癌患者比较,IL-1RN-2018T/C基因型分布及等位基因频率差异无统计学意义(P>0.05)。(3)NSCLC组患者的血清中IL-1Ra、IL-1β水平显著高于对照组,IL-1Ra/IL-1β低于对照组,差异有统计学意义(P<0.05)。(4)NSCLC组中各基因型患者的血清IL-1Ra水平差异无统计学意义(P>0.05)。结论IL-1RN-2018的C等位基因携带者的NSCLC患病风险增加;IL-1Ra/IL-1β的降低可能预示NSCLC患病风险。

Objective To investigate the association between interleukin receptor antagonist （IL-1Ra） encoded genes（IL- 1RN-2018） polymorphisms and serum IL-1Ra/IL-1β with non-small cell lung cancer （NSCLC）. Methods Totally 85 cases of NSCLC were selected as the NSCLC group and 80 cases of healthy physical examination were selected as the control group from January 2012 to January 2014. The IL-1RN-2018 T/C gene polymorphisms of the two groups were determined with the fluorescence quantitative PCR technique based on high resolution melting, 10% randomly selected samples were sequenced to prove the accuracy. The levels of IL-1Ra and IL-1β of two groups were determined with ELISA. Results （1）The onset risk of NSCLC in TC and TC-t-CC genotypes on IL-1RN-2018 site in the NSCLC group were increased by 2. 646 times and 2. 315 times respectively compared with TT genotype, the difference had statistical significance（P〈0.05）. （2）No statistically significant difference of IL-1RN-2018 T/ C were found between patients with squamous cell carcinoma and adenocarcinomas（P〉0.05）. （3）The serum IL-1Ra and IL-1β levels in the NSCLC group were significantly higher than those in the control group, but IL-1Ra/IL-1β in the NSCLC group was significantly lower （P〈0. 05）. （4）The serum IL-1Ra levels in the NSCLC group had no statistically significant difference among genotypes （P〉0.05）. Conclusion The C allele in IL-1RN-2018 site may increase the onset risk of NSCLC;the reduction of serum IL- 1Ra/IL-1β may presage the risk of NSCLC.